Dermata Therapeutics Inc 2026年季度报告

FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period EndedJune 30, 2026 For the Transition Period from ___________ to ___________ Commission File Number:001-40739 DERMATA THERAPEUTICS, INC. (Exact name of registrant as specified in the charter) Registrant’s telephone number, including area code:858-800-2543 Securities registered pursuant to Section 12(b) of the Act: Common Stock, par value $0.0001 per shareWarrants, exercisable for one share of CommonStock The Nasdaq Capital MarketThe Nasdaq Capital Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days.☒Yes☐No. Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files).☒Yes☐No. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act.☒ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).☐Yes☒No. There were 4,022,143 shares of Common Stock, par value $0.0001, of Dermata Therapeutics, Inc. issued and outstanding as of August10, 2026. DERMATA THERAPEUTICS, INC.Form 10-QTable of Contents Page No.Part IFinancial Information3Item 1:Financial Statements (unaudited)3Balance Sheets3Statements of Operations4Statements of Stockholders’ Equity5Statements of Cash Flows7Notes to Financial Statements8Item 2:Management’s Discussion and Analysis of Financial Condition and Results of Operations24Item 3:Quantitative and Qualitative Disclosures about Market Risk33Item 4:Controls and Procedures33Part IIOther Information34Item 1:Legal Proceedings34Item 1A:Risk Factors34Item 2:Unregistered Sales of Equity Securities and Use of Proceeds35Item 3:Defaults Upon Senior Securities35Item 4:Mine Safety Disclosures35Item 5:Other Information35Item 6:Exhibits36Signatures372 DERMATA THERAPEUTICS, INC.Balance Sheets DERMATA THERAPEUTICS, INC.Statements of Stockholders’ Equity(unaudited) DERMATA THERAPEUTICS, INC.Statements of Stockholders’ Equity(unaudited) DERMATA THERAPEUTICS, INC.Statements of Cash Flows(unaudited) DERMATA THERAPEUTICS, INC.Notes to Financial Statements(unaudited) 1. Organization and Basis of Presentation Dermata Therapeutics, Inc., (the “Company”), was formed in December 2014 as a Delaware limited liability company(“LLC”) under the name Dermata Therapeutics, LLC. On March 24, 2021, the Company converted from an LLC to a Delaware C-corporation and changed its name to Dermata Therapeutics, Inc. On August 17, 2021, the Company completed its initial publicoffering. The Company’s shares of Common Stock and warrants are listed on the Nasdaq Stock Market LLC (“Nasdaq”) under thesymbols “DRMA,” and “DRMAW,” respectively. During September 2025, the Company made a strategic shift from researching anddeveloping prescription products to becoming a science-driven leader in dermatologic solutions anticipating the launch of its firstdirect-to-consumer (“DTC”) products from its Tome skincare, expected on August 25, 2026. Reverse Stock Splits On July 15, 2025, the Company held its annual meeting of stockholders at which time the stockholders approved the adoptionof an amendment to its Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split of its issued andoutstanding shares of Common Stock, at a specific ratio, ranging from one-for-two to one-for-thirty, with the exact ratio determined bythe Company’s board of directors without further approval or authorization of its stockholders. On August 1, 2025, the Companyeffected the reverse split of its shares of Common Stock at a ratio of 1-for-10, as approved by the Company’s board of directors (the“2025 Reverse Stock Split”). The par value was not adjusted as a result of the 2025 Reverse Stock Split. All issued and outstandingshares of Common Stock and per share amounts contained in the financial statements have been retroactively adjusted to reflect thisreverse stock split for all periods presented. Li